NasdaqGS:CNST

Stock Analysis Report

Executive Summary

Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance.


Snowflake Analysis

Excellent balance sheet with weak fundamentals.

Share Price & News

How has Constellation Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CNST's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

26.2%

CNST

4.7%

US Biotechs

9.9%

US Market


1 Year Return

141.3%

CNST

-0.4%

US Biotechs

-11.9%

US Market

Return vs Industry: CNST exceeded the US Biotechs industry which returned 0% over the past year.

Return vs Market: CNST exceeded the US Market which returned -11.5% over the past year.


Shareholder returns

CNSTIndustryMarket
7 Day26.2%4.7%9.9%
30 Day-7.5%-6.7%-15.0%
90 Day-29.8%-8.6%-21.5%
1 Year141.3%141.3%0.4%-0.4%-10.0%-11.9%
3 Yearn/a9.3%6.6%12.3%5.1%
5 Yearn/a-6.4%-10.6%32.5%18.1%

Price Volatility Vs. Market

How volatile is Constellation Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Constellation Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

4.04x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: CNST ($32.69) is trading above our estimate of fair value ($5.02)

Significantly Below Fair Value: CNST is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: CNST is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: CNST is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CNST's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CNST is overvalued based on its PB Ratio (4x) compared to the US Biotechs industry average (2.5x).


Next Steps

Future Growth

How is Constellation Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?

14.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CNST is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CNST is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CNST is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if CNST's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if CNST's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: CNST is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Constellation Pharmaceuticals performed over the past 5 years?

-42.8%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: CNST is currently unprofitable.

Growing Profit Margin: CNST is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if CNST's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare CNST's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CNST is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (22%).


Return on Equity

High ROE: CNST has a negative Return on Equity (-25.34%), as it is currently unprofitable.


Next Steps

Financial Health

How is Constellation Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: CNST's short term assets ($387.0M) exceed its short term liabilities ($22.8M).

Long Term Liabilities: CNST's short term assets ($387.0M) exceed its long term liabilities ($38.8M).


Debt to Equity History and Analysis

Debt Level: CNST's debt to equity ratio (8.8%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if CNST's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: CNST has a low level of unsold assets or inventory.

Debt Coverage by Assets: CNST's debt is covered by short term assets (assets are 13.1x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CNST has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: CNST has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -28.7% each year


Next Steps

Dividend

What is Constellation Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CNST's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate CNST's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CNST's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CNST's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CNST's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.9yrs

Average management tenure


CEO

Jigar Raythatha

3s

Tenure

US$4,703,254

Compensation

Mr. Jigar Raythatha has been the President, Chief Executive Officer and Director of Constellation Pharmaceuticals, Inc. since March 2017. Mr. Raythatha served as the Chief Business Officer at Jounce Therap ...


CEO Compensation Analysis

Compensation vs Market: Jigar's total compensation ($USD4.70M) is about average for companies of similar size in the US market ($USD4.54M).

Compensation vs Earnings: Jigar's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Jigar Raythatha
President3yrsUS$4.70m0.036% $489.1k
Emma Reeve
Senior VP2.42yrsUS$1.44mno data
Adrian Senderowicz
Senior VP & Chief Medical Officer2.67yrsUS$1.13m0.038% $519.3k
Danny Reinberg
Co-Founder12.17yrsno datano data
Yang Shi
Co-Founder12.17yrsno datano data
David Allis
Co-Founder12.17yrsno datano data
Brenda Sousa
Senior Vice President of Human Resources & Operations2.92yrsno datano data
Patrick Trojer
Chief Scientific Officer1.33yrsno datano data
Ronald Aldridge
Senior Director of Investor Relationsno datano datano data
Karen Valentine
Chief Legal Officer & General Counsel1.67yrsno datano data

2.9yrs

Average Tenure

55yo

Average Age

Experienced Management: CNST's management team is considered experienced (2.9 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Jigar Raythatha
President3yrsUS$4.70m0.036% $489.1k
Robert Tepper
Independent Director11.92yrsUS$21.64kno data
Mark Goldsmith
Chairman of the Boardno dataUS$204.51k0.34% $4.7m
David Livingston
Member of the Scientific Advisory Boardno datano datano data
Scott Lowe
Member of the Scientific Advisory Boardno datano datano data
Elizabeth Trehu
Independent Director1.5yrsUS$177.29kno data
James Audia
Director2.67yrsUS$230.33k0.093% $1.3m
Steven Hoerter
Independent Director1.5yrsUS$177.29kno data
Padmanee Sharma
Member of Scientific Advisory Board2.83yrsno datano data
Robert Schreiber
Member of Scientific Advisory Board2.83yrsno datano data

2.8yrs

Average Tenure

60.5yo

Average Age

Experienced Board: CNST's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 134.9%.


Top Shareholders

Company Information

Constellation Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Constellation Pharmaceuticals, Inc.
  • Ticker: CNST
  • Exchange: NasdaqGS
  • Founded: 2008
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.367b
  • Shares outstanding: 41.81m
  • Website: https://www.constellationpharma.com

Number of Employees


Location

  • Constellation Pharmaceuticals, Inc.
  • 215 First Street
  • Suite 200
  • Cambridge
  • Massachusetts
  • 2142
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CNSTNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDJul 2018

Biography

Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company’s lead product candidates include CPI-0610 that is in Phase II clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib; and CPI-1205 that is in Phase Ib/II clinical trials for the treatment of metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors. It is also developing CPI-0209, which is in preclinical trials for the treatment of solid tumors. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in March 2008. Constellation Pharmaceuticals, Inc. was founded in 2008 and is based in Cambridge, Massachusetts. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/03/29 03:32
End of Day Share Price2020/03/27 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.